The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Open accessAbstract
BACKGROUND: mutations. METHODS: mutations. In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, administered intrathecally for 12 weeks. The primary outcomes were safety and pharmacokinetics. The secondary outcome was the change from baseline in the cerebrospinal fluid (CSF) SOD1 concentration at day 85. Clinical function and vital capacity were measured. RESULTS: A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses. Lumbar puncture-related adverse events were observed in most participants. Elevations in CSF white-cell count and protein were reported as adverse events in 4 and 5 participants, respectively, who received tofersen. Among participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the placebo group died from respiratory failure on day 52. The difference at day 85 in the change from baseline in the CSF SOD1 concentration between the tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for the 100-mg dose. CONCLUSIONS: mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar puncture-related adverse events were observed in most participants. (Funded by Biogen; ClinicalTrials.gov number, NCT02623699; EudraCT number, 2015-004098-33.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ASO injection is a current standard of care for the fatal childhood disease spinal muscular atrophy15 and is in five ongoing Phase I trials in ALS, Parkinson’s, and Alzheimer’s diseases and in Phase III trials for inherited ALS from a mutation in superoxide dismutase16,17 and for Huntington’s disease18.”
From Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTB (2021) · cites this paper as [17]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Experience from Alzheimer’s disease (AD), spinal muscular atrophy (SMA),5 and amyotrophic lateral sclerosis (ALS)6 suggests treating FTD will be most successful if treatment is initiated early in the disease course, ideally prior to the onset of symptoms.”
From Temporal order of clinical and biomarker changes in familial frontotemporal dementia (2022) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Self-citationNusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Self-citationNon–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond
Ilieva, H., Polymenidou, M., & Cleveland, D. W. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908164 · Cited by 1,008
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis
Cudkowicz, M., McKenna‐Yasek, D., Sapp, P. C., Chin, W., Geller, B. A., Hayden, D. L., Schoenfeld, D., Hosler, B. A., Horvitz, H. R., & Brown, R. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410212 · Cited by 533
Self-citationAntisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics
Abel, O., Powell, J. F., Andersen, P. M., & Al‐Chalabi, A. (2012) · Human Mutation · doi:10.1002/humu.22157 · Cited by 341
Self-citationIs SOD1 loss of function involved in amyotrophic lateral sclerosis?
Saccon, R. A., Bunton-Stasyshyn, R. K. A., Fisher, E., & Fratta, P. (2013) · Brain · doi:10.1093/brain/awt097 · Cited by 339
Andersen, P. M., Nilsson, P., Ala‐Hurula, V., Keränen, M.-L., Tarvainen, I., Haltia, T., Nilsson, L., Binzer, M., Forsgren, L., & Marklund, S. L. (1995) · Nature Genetics · doi:10.1038/ng0595-61 · Cited by 323
Self-citationAndersen, P. M. (1997) · Brain · doi:10.1093/brain/120.10.1723 · Cited by 301
Self-citation
Cited by
Sorted by citations
Items 501–565 of 565
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4801-1
Therapeutic strategies based on genetic interventions
Baek, R. C., Finn, P. F., & Martini, P. G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00013-6
Welche Therapieansätze gibt es bei der amyotrophen Lateralsklerose?
Ludolph, A. C., & Lang, C. (2024) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-3938-3
Self-citationAlfahel, L., Rajkovic, A., & Israelson, A. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00616
“Tofersen, an antisense oligonucleotide designed to reduce the synthesis of the SOD1 protein, has recently been approved by the FDA for treating SOD1 ALS (Miller et al., 2020, 2022).”
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
Lane, R. M., & Bennett, C. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00039-x
Self-citationRare Diseases and Antisense Oligonucleotides: A Mirage or Miracle
Vaddadi, H., & Oroszi, T. L. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.1212003
Update Amyotrophe Lateralsklerose – Diagnostik und Therapie
Bjelica, B., Petri, S., & Wohnrade, C. (2024) · Neurologie up2date · doi:10.1055/a-2133-1668
RNA-based therapeutics—Mechanisms and challenges
Khan, G. A., & Shahiwala, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00007-1
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00033-7
Neuhofer, C. M., Gasser, T., & Klopstock, T. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00027-1
Zhu, Y., Bai, J., Wang, H., Li, M., Yang, F., Pang, X., Du, R., Zhao, J., Huang, X., & Cui, F. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2554224
5) Nucleic Acid Therapeutics for Rare Neurological Diseases
Nakayama, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1587
Factors influencing the progression of amyotrophic lateral sclerosis: prospective cohort study
Smirnova, A. Y., Сергеевич, Д. Д., Alekseeva, T. M., & Demeshonok, V. S. (2025) · Neuromuscular Diseases · doi:10.17650/2222-8721-2025-15-2-37-47
Pezet, S., Hua, J., Marais, T., Delamare, M., Elouej, S., Lemos, J. P., Castiglione, A., Astord, S., Cohen-Tannoudji, M., Pêche, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682744
Tomlinson, J., Roberson, E., Klee, V., Ma, J., & Roggenbuck, J. (2025) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2025.2582829
Casals-Sendra, G., Jarne-Sanz, I., Catasús, N., Boluda-Luis, I., Quer, A., Amilibia, E., Lázaro, C., Serra, E., Blanco, I., & Castellanos, E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.14.688164
Trist, B. G., Fifita, J. A., Hogan, A. L., Grima, N., Smith, B. N., Troakes, C., Vance, C. A., Shaw, C. E., Al-Sarraj, S., Blair, I. P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20652143
Liao, Y., Cai, H., Luo, F., Li, D., Li, H., Liao, G., Duan, J., Renshi, X., & Zhang, X. (2023) · Figshare · doi:10.6084/m9.figshare.22613693
Freigang, M., Steinacker, P., Wurster, C. D., Schreiber‐Katz, O., Osmanovic, A., Petri, S., Koch, J. C., Rostasy, K. M., Falkenburger, B. H., Ludolph, A. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15071519
Self-citationFreigang, M., Steinacker, P., Wurster, C. D., Schreiber‐Katz, O., Osmanovic, A., Petri, S., Koch, J. C., Rostasy, K. M., Falkenburger, B. H., Ludolph, A. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15071513
Self-citationFreigang, M., Steinacker, P., Wurster, C. D., Schreiber‐Katz, O., Osmanovic, A., Petri, S., Koch, J. C., Rostasy, K. M., Falkenburger, B. H., Ludolph, A. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15071516
Self-citationZucchi, E., Bonetto, V., Sorarù, G., Martinelli, I., Parchi, P., Liguori, R., & Mandrioli, J. (2020) · Figshare · doi:10.6084/m9.figshare.13101124
Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis
Karros, M., DiFulco, M., & Nogid, A. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280251408862
“14,16 There are hundreds of pathogenic variants of the SOD1 gene, making it challenging in many cases to definitively classify whether a given variant is disease-causing or confers an increased risk of developing ALS.”
Gene-targeted versus broad-spectrum therapies in ALS: comparative lessons and strategic outlook
Shen, Y. Q., Shen, S., & Luo, Z. (2026) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2026.01.012
Safety profile of tofersen in amyotrophic lateral sclerosis: a systematic review and meta-analysis
Tarazona‐Santabalbina, F. J., Belenguer‐Varea, Á., Borrás-Blasco, J., García-Tercero, E., Martín, M. L., Prior, N. P., Mariscal, G., & Valcuende‐Rosique, A. (2026) · Neurological Sciences · doi:10.1007/s10072-025-08793-5
“In this context, patterns of frequent, largely manageable adverse events, but the small size of individual cohorts limited generalizability [7, 12, 13, 15–17].”
InfluentialRomano, R., Ruotolo, G., Perrone, F., Tomaselli, S., Mazzoni, M., Spataro, R., Conforti, F. L., Rosati, J. D., & Bucci, C. (2026) · Biomolecules · doi:10.3390/biom16030393
“It has demonstrated therapeutic effectiveness in reducing SOD1 levels, resulting in reduced neuronal damage and slowed disease progression [34,35].”
Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA
Kaymaz, A. Y., Bora, G., Erdem‐Yurter, H., & Grunseich, C. (2026) · Genes · doi:10.3390/genes17040419
“ALS patients with SOD1 mutations received ascending doses of Tofersen by intrathecal administration over a period of 12 weeks in phase I/II [131].”
Comprendre et modéliser la Sclérose Latérale Amyotrophique à début précoce
Muratet, F. (2022) · theses.fr (ABES) · doi:10.70675/9a7778aaz88c7z40b1z92d3zaf5699b86a09
Genetic contributions to mitochondrial dysfunction in amyotrophic lateral sclerosis etiology
Russell, N. D., Downie, J. M., Bromberg, M. B., Pulst, S. M., & Jorde, L. B. (2026) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2026.100614
Giordano, A., Mandrioli, J., Cerri, F., Lunetta, C., Saebfar, H., Catania, M., Battipaglia, C., Leone, L., Trojsi, F., Vizziello, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104208
Agianda, H. A. P., & Ebrahimi‐Fakhari, D. (2026) · Movement Disorders · doi:10.1002/mds.70376
RNA-centric approaches in amyotrophic lateral sclerosis: prospects for future therapeutics
Cognata, V. L., Gentile, G., Morello, G., Guarnaccia, M., & Cavallaro, S. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2682782
“It is currently undergoing confirmatory evaluation in the Phase 3 ATLAS trial, to evaluate the safety and efficacy of initiating tofersen in individuals with pre-symptomatic ALS carrying SOD1 mutations [56–60].”
Concepts, types, and treatment strategies for neurodegenerative disorders
Rana, R., Jaiswal, S., Sethi, M., Tripathi, S., Mishra, K., Gupta, P., & Chourasia, M. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00003-9
De novo design of microprotein in neurodegenerative diseases
Das, A. K., & Borah, M. (2026) · Discover Molecules · doi:10.1007/s44345-026-00058-8
Zhu, Y., Li, M., Wang, Z., & Gu, X. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107511
Demeret, R., Vieles-Marais, D., Treiner, E., Acket, B., Fabry, V., Levade, T., Nogueira, L., Pages, J.-C., & Cintas, P. (2026) · Revue Neurologique · doi:10.1016/j.neurol.2026.05.005
Phase separation and protein aggregation in neurodegenerative diseases
Seiglière, H. D. L., Letourneur, Æ., Ichas, F., & Giorgi, F. D. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107678 · Cited by 1
History and future of RNA medicines
Hovnanian, A., Mondon, G., & Titeux, M. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.05.023
Multiplex Panel Detects Glial and Inflammatory Biomarker Signatures in Sporadic and C9orf72-ALS
Baskar, K., Steffke, C., Bernsen, S., Elmas, Z., Hesebeck‐Brinckmann, J., Schuster, J., Meyer, T., Weydt, P., Weishaupt, J. H., Brenner, D., et al. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200618
“…has also been associated with in fl ammatory adverse events, including activation of innate immune pathways and cytokine release in the CSF. 19,20,35,36 In this context, biomarkers such as CHIT1, CHI3L1, CCL2, and CCL3 may be particularly valuable as pharmacodynamic and safety readouts,…”
InfluentialDiagnostik und Therapie der Amyotrophen Lateralsklerose
Dorst, J. (2026) · DGNeurologie · doi:10.1007/s42451-026-00908-2
Casals-Sendra, G., Jarne-Sanz, I., Catasús, N., Boluda-Luis, I., Quer, A., Amilibia, E., Plotkin, S. R., Lázaro, C., Serra, E., Blanco, I., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103046
“33 Additionally, there is evidence of autosomal dominant diseases that also respond, including retinitis pigmentosa (RP), 34 amyotrophic lateral sclerosis, 35 or Huntington’s disease.”
Cerebellar ataxia-onset ALS with SOD1 D91A mutation: a rare phenotype
Shevchuk, D. V., Нужный, Е. П., Fedotova, E. Y., Ершова, М. В., Вячеславович, М. И., Anikin, G. A., Романовна, П. А., Abramycheva, N. Y., Zakharova, M. N., & Illarioshkin, S. N. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1889931
Evaluation of Antisense Oligonucleotide-Associated Neuronal Lysosomal Changes
Mondragon, A. A., Donovan, K. W., Hronowski, X. L., Swalley, S. E., Lamore, S., Gao, B., Massol, R., Lamb, M., Grubor, B., Meier, W., et al. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261473518
RNA interference (RNA)-based therapeutics for treating neurodegenerative diseases
Mahjoubin‐Tehran, M., & Sahebkar, A. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2722300
Laginha, I., Schmitz, M., Correia, A. D. S., Saleem, T., Correia, S., Zafar, S., Younas, N., Canaslan, S., Goebel, S., Root, E., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag321
“30,31 These findings have positioned PrP-lowering strategies at the forefront of potential therapeutic approaches.”
Intrathecal Therapies for Neurodegenerative Diseases
Menéndez‐González, M. (2026) · Neuromethods · doi:10.1007/978-1-0716-5241-1_10
Bertier, S. D., Amador, M. D. M., Guissart, C., Miki, T., Boillée, S., Lobsiger, C. S., Bohl, D., Fauret‐Amsellem, A., Bohic, A., Brainbank Neuro-CEB Neuropathology Network, et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03075-6
Self-citationStreicher, N. S. (2026) · Muscle & Nerve · doi:10.1002/mus.70397
Huang, C.-C. S., Sanchez-Santos, C., Martínez-González, L., Gil, C., & Martı́nez, A. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2729512
“Early phase I/II data showed dose-dependent reductions in cerebrospinal fluid (CSF) of SOD1 concentrations together with an acceptable safety profile, supporting progression to the phase III VALOR trial (NCT02623699) [19].”
Ahmadi, A. M., & Khatibi, V. (2026) · Soft Computing · doi:10.1007/s00500-026-11424-6
Padhiyar, D., Butani, S., Vyas, T., Mukharya, A., & Rajput, A. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03469-5
Ricotti, V., Fogel, A., Vandenbosch, M., Cerri, F., Ala, P., Capstick, A., Rossi, R., Gerardi, F., Jacobs, R., Mercuri, E. M., et al. (2026) · medRxiv · doi:10.64898/2026.09.23.26363372
Self-citationDevelopment of Antisense Oligonucleotide Gapmers for Amyotrophic Lateral Sclerosis
Nakamura, Y., Moriyama, H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_10
Wu, K., Gao, C., Fu, S., Li, Y., Li, Z., Han, X., Zhang, Y., Zhang, Y., & Wang, Y. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103726
“In addition, direct intrathecal administration is highly invasive, making it unsuitable for long-term and repeated treatment [24,25].”
Ohara, M., Ishigaki, S., Watts, J. K., Yamada, K., Ikezu, T., & Ikezu, S. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00044-x
The Role of SOD1 and Oxidative Stress in Amyotrophic Lateral Sclerosis: An Overview
Gómez-Pérez, C. A., Ramírez-García, M. Á., & Yescas, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209084
“However, the clinical benefits have been modest thus far, with changes in biomarkers (e.g., CSF SOD1 and NfL) proving to be more consistent than functional outcomes [113,115].”
Swindell, W. R., Ali, A. T., Iacoangeli, A., & Bhai, S. F. (2026) · Brain Sciences · doi:10.3390/brainsci16101120
“Patients carrying SOD1 mutations, however, have shown improved biomarker profiles following antisense oligonucleotide therapy [5,6].”
InfluentialAntisense Oligonucleotides as Precision Therapies for Neurodegenerative Diseases: A Narrative Review
Mohebbi, S., Ghanbari, M., & Hassanlou, M. (2026) · Jentashapir Journal of Cellular and Molecular Biology · doi:10.5812/jjcmb-169275
“Importantly, the study provided evidence that treated patients also experienced decreases in biomarkers, specifically neurofilament proteins, which correlated with clinical improvement, supporting the potential of ASOs to slow ALS progression (26, 59).”
Beyond Monogenic Inheritance: Emerging Genetic Architecture of Amyotrophic Lateral Sclerosis
Ramadan, S., Panza, E., & Orlacchio, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209350
siRNA therapeutics: from hepatic delivery to extrahepatic targeting
Wang, N., Meng, L., Shi, J.-X., & Bartneck, M. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2754564
Okoshi, K., & Aoki, Y. (2026) · Journal of Human Genetics · doi:10.1038/s10038-026-01522-6
Motor Neuron Induction and Differentiation
Flores, A. F., Haghi, G., Chaineau, M., Chen, X., Rocha, C., Rao, T., & Durcan, T. M. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3367775
Ren, W., Meng, R., Liang, T., Yang, X., & Wang, T. (2026) · Acupuncture & Electro-Therapeutics Research · doi:10.1177/03601293261499859
Characterization of plasma misfolded superoxide dismutase 1 in amyotrophic lateral sclerosis
Kuo, Y.-C., Ting, C.-H., Lai, H., Huang, P.-Y., Shih, Y.-A., Yang, C.-C., Cheng, L.-F., Tai, S.-T., Chao, C., Chang, H., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107669
Metadata
- Authors
- Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., Maragakis, N. J., McDermott, C. J., Pestronk, A., Ravits, J., Salachas, F., Trudell, R., Van Damme, P., Zinman, L., Bennett, C. F., Lane, R., Sandrock, A., Runz, H., Graham, D., Houshyar, H., McCampbell, A., Nestorov, I., Chang, I., McNeill, M., Fanning, L., Fradette, S., & Ferguson, T. A.
- Affiliations
- From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) — both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching...
- Harvard University (US)
- Montreal Neurological Institute and Hospital (CA)
- Barrow Neurological Institute (US)
- Biogen (United States) (US)
- ORCID
- Cudkowicz, Merit
- Shaw, Pamela J.
- Andersen, Peter M.
- Atassi, Nazem
- Bucelli, Robert C.
- Genge, Angela
- Glass, Jonathan
- Ladha, Shafeeq
- Maragakis, Nicholas J.
- McDermott, Christopher J.
- Pestronk, Alan
- Ravits, John
- Trudell, Randall
- Zinman, Lorne
- Bennett, C. Frank
- Lane, Roger
- Runz, Heiko
- Graham, Danielle
- McCampbell, Alexander
- Nestorov, Ivan
- Chang, Ih
- Fradette, Stephanie
- Ferguson, Toby A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-07-09
- Volume
- 383
- Issue
- 2
- Pages
- 109-119
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3040840440
- Cited by
- 565
- References
- 27
- Citations by year
- 2026: 64 · 2025: 73 · 2024: 87 · 2023: 90 · 2022: 130 · 2021: 83 · 2020: 36
- FWCI
- 36.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (NF-SI-0617-10077)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- tofersen, antisense oligonucleotides, amyotrophic lateral sclerosis, SOD1, intrathecal administration, pleocytosis, dose escalation
- MeSH terms
- Superoxide Dismutase-1, Adult, Amyotrophic Lateral Sclerosis, Dose-Response Relationship, Drug, Double-Blind Method, Female, Headache, Humans, Injections, Spinal, Intermediate Filaments, Leukocytosis, Male, Middle Aged, Mutation, Oligonucleotides, Vital Capacity, Oligonucleotides, Antisense, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
